How to Verify a GP's Track Record When the Deals Were Done at a Prior Firm

Every emerging manager deck has the same slide. Twelve logos, a gross IRR in the 30s, and the line "I was involved in these deals." What that slide almost never tells you is whether the general partner (GP, the person who runs the fund and makes investment decisions) sourced the deal, led the negotiation, sat on the board, or showed up to two meetings as the fourth person on a six-person team. The Institutional Limited Partners Association (ILPA), the trade group whose Due Diligence Questionnaire (DDQ) 2.0 is the closest thing private markets has to a standard diligence form, devotes an entire section to track record for exactly this reason. Attribution is not a footnote here. For a first-time or second-fund manager, it is often the single most important thing you can verify, because it is what decks are most likely to overstate. I have sat across from dozens of GPs raising a debut fund, and the attribution gap is rarely outright fraud. It is usually softer: a former vice president at a mid-market buyout shop describing herself as having "led" eight deals when she co-led two and sourced one, with the rest being deals she analyzed as part of a five-person team. That distinction changes what you are underwriting. You are not buying twelve data points. You are buying one person's judgment, and you need to know how much of that judgment actually touched the deals on the slide.

Why attribution gets fuzzy in pitch decks

The fuzziness is structural, not accidental. Private equity, venture, and real estate deals are almost always team efforts. A single transaction might involve a partner who sourced the relationship, an associate who ran the model, a VP who led diligence, and a managing director who closed the term sheet and took the board seat. When that VP leaves to raise her own fund three years later, the deal does not cleanly belong to any one person. It belongs to the firm. But a pitch deck needs a track record slide, and "the firm I used to work at did well" is not fundable. So the deal gets folded into "my track record," in language soft enough to be defensible but misleading enough to move a term sheet. This is also about incentives. The GP wants credit. The placement agent wants a clean story. And the LP, especially a first-time allocator to alternatives, wants to believe the deck because the alternative is a longer, more uncomfortable process. Cambridge Associates data cited in industry commentary on emerging managers shows the top-quartile spread in net IRR between first-time and established managers is narrow, often around 150 basis points, which tells you emerging managers can perform. It does not tell you whether the person in front of you is the reason the prior fund performed. Those are different questions, and pitch decks are built to make you conflate them.

The SEC Marketing Rule and what "related performance" actually allows

This is not just a diligence best practice. It is federal securities law for SEC-registered advisers. The SEC's Investment Adviser Marketing Rule, formally Rule 206(4)-1 under the Investment Advisers Act of 1940, took full compliance effect in November 2022 and addresses what advisers can say about performance earned somewhere else. The rule uses a defined term, "predecessor performance," for exactly this scenario: a GP advertising results from a fund managed at a prior firm. Under the rule, predecessor performance can only appear in an advertisement if three conditions hold. The people who actually managed the prior track record must be the ones now managing accounts at the new firm. The prior account has to be similar enough to the current one that using its numbers is not misleading. And the advertisement must disclose, clearly and prominently, that the results came from a prior entity. As a compliance analysis from Troutman Pepper Locke on the Marketing Rule puts it, the rule allows performance to be attributed only to "the persons who were primarily responsible for achieving the prior performance results." That phrase, "primarily responsible," does a lot of work. It is not "present for" or "exposed to." A GP who was one of six people on a deal team was not primarily responsible for it, and should not advertise it as predecessor performance without real qualification. The rule also restricts "related performance" and "extracted performance," meaning a firm generally cannot cherry-pick its best deals out of a larger portfolio without disclosing the whole portfolio those deals came from. A fund deck with twelve winners and no mention of the deals that did not make the cut mirrors what the Marketing Rule was built to prevent, even if the manager is not SEC-registered and technically outside its reach. Many emerging managers below certain thresholds are exempt reporting advisers, not full registrants, so the rule may not bind them legally. That makes your own diligence more important, not less. The SEC has also pursued outright fabrication. In a September 2024 settled action against Crawford Ventures Absolute Return Fund principal Evan Katz, the SEC found the fund had marketed a trading track record backed by a fake "Performance Audit" from an Australian firm that had never done any work for the traders involved. The fund had already raised more than $16 million before the fabrication surfaced. Katz paid roughly $98,500 in disgorgement plus a matching penalty for failing to verify the track record before using it. Most attribution problems you meet are milder. But the case is a useful anchor: the SEC's theory of liability rested on the marketer's failure to confirm a track record, the same failure this guide asks you to avoid.

Red flags in the deck and the data room

Certain phrases and omissions are diagnostic. None prove fraud on their own, but each should slow you down and generate a follow-up question.

• Vague verbs. "Involved in," "worked on," "part of the team that," and "contributed to" all do the same job: claiming proximity to a good outcome without claiming responsibility for it.
• No named deal lead. A track record table that lists deals, dates, and multiples but never names who led each one is built to obscure attribution, not reveal it.
• Missing or vague dates. If the deck will not tell you exactly when the GP joined the deal team, left the prior firm, and when the deal closed, you cannot rule out that they had left before the good outcome happened.
• No distinction between sourcing, leading, and observing. Sourcing a deal, leading negotiation, and sitting in on committee meetings as a junior team member are three jobs with three different weights. A deck that flattens them hides the weighting from you.
• Selective inclusion. A track record showing twelve winners from a portfolio of thirty or forty deals, with no accounting for the rest, mirrors the extracted-performance problem the Marketing Rule was built to police.
• No attribution letter and no explanation for its absence. A written attribution letter from a prior firm is the closest thing to a gold-standard confirmation. Its absence is not disqualifying, but the GP should explain why they do not have one and what they are offering instead.
• Reluctance to name references at the prior firm. A GP who left on good terms and genuinely led the deals they claim should be eager to hand you names.

The question script: what to actually ask on the call

Generic questions get generic answers. Ask for the walk-through and watch where the story gets vague.

• "Walk me through this deal from the first meeting to the exit. Who brought it in the door?" A GP who truly led a deal can narrate it in sequence, with names, without hedging.
• "What was your title and formal role at the time, and who had final investment committee sign-off?" You want the org chart, not the highlight reel.
• "Of the deals on this slide, which did you source independently, which did you co-lead, and which were you staffed on without sourcing or leading?" Make the GP do the sorting in front of you. Precision here is the single best signal on the call.
• "Can I get a written attribution letter from your prior firm?" If yes, get it before you move further. If no, ask what they can offer instead, such as a signed reference or a board seat documented in Crunchbase or PitchBook.
• "Who else was on this deal team, and can I speak with them?" A GP confident in their attribution will not flinch.
• "What happened on the deal that went wrong, and what was your role in that one?" How a GP attributes blame tells you as much as how they claim credit.
• "Did you leave your prior firm on good terms, and would they confirm this track record if I called them directly?" This tests whether the attribution would survive an off-list call.

What good attribution documentation looks like

The gold standard, per guidance from placement agents like Monument Group on first-time fundraises, is a full written attribution letter from the prior firm, ideally negotiated before the GP departs, since cooperation tends to decline afterward. That letter should state which investments the GP was responsible for, in what capacity, tied to dates. A framework for what belongs in that documentation, described in Silicon Valley Bank's guidance on building an investment track record, calls for attribution broken out by named partner for every deal, with co-investors listed separately so you can call them too. Absent a full letter, a narrower confirmation naming the deals where the GP played a senior role is still useful. Below that, you are working with a paper trail: press releases naming the GP, a verifiable board seat, and a signed reference from the CEO who worked with the GP directly. Deal-level detail matters more than fund-level summary statistics. You want a table with the company name, sector, entry and exit dates, the GP's attribution (sourced, co-led, led, board member, or staffed), co-investor names, and gross and net multiples or IRR broken out deal by deal, not blended across the whole claimed portfolio. A prior firm will often restrict financial detail, since venture and private equity commentary on attribution letters treats fund performance as the firm's confidential property, not the individual's. A qualitative deal list with verifiable public facts and permissioned references can substitute, as long as the GP explains why hard numbers are missing. Cross-reference too. Check the GP's Form ADV, if one exists, through the SEC's public disclosure database for names, dates, and disciplinary history. Check Crunchbase or PitchBook for the GP's name attached to specific deals and board seats. None of this fully confirms who led a deal internally, but it corroborates the timeline the GP gives you, and a mismatch between claim and public record is worth walking away over. None of this eliminates risk. A fully attributed, reference-checked track record still tells you only what one person did under a different fee structure, fund size, and market. A strategy that worked leading $15 million deals inside a $2 billion platform may not repeat at a $75 million debut fund where the same person sources, negotiates, and manages the entire pipeline alone. Attribution answers whether the track record is real. It does not answer whether it will transfer.

Frequently Asked Questions

What exactly is an attribution letter, and who provides it?

An attribution letter is a written statement from a GP's prior firm confirming which investments that individual was responsible for and in what capacity, such as sourcing, leading, or serving on the board. The prior firm provides it, typically its general counsel or managing partner, and it is the strongest verification available because it comes from the party with the fullest internal record of who did the work.

Does the SEC Marketing Rule apply to every emerging manager pitching me?

No. Rule 206(4)-1 applies to SEC-registered advisers. Many emerging managers raising a debut fund operate below registration thresholds as exempt reporting advisers, so they are not legally bound by the Marketing Rule's predecessor and related performance provisions. That is exactly why your own diligence matters more with smaller, newer managers, since the regulatory backstop may not apply to them.

What if the GP's prior firm refuses to provide any written attribution letter or confirmation?

Treat refusal as a data point, not an automatic disqualifier. Prior firms often decline for confidentiality reasons unrelated to the departing GP's honesty. Ask for an alternative path: a signed reference from a portfolio company executive, a documented board seat in a deal database, or press coverage naming the GP. Then verify those alternatives through off-list reference calls rather than relying solely on names the GP supplies.

How many reference calls should I make before I trust a claimed track record?

Industry practice among institutional allocators typically runs ten to twenty calls per fund commitment, several of them off-list calls to people the GP did not select, such as former colleagues, co-investors, or portfolio company executives. For the attribution question specifically, prioritize at least two or three calls to people who sat on the same deal team, since they can confirm or contradict the specific claim of who led what.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.